期刊文献+

人血型B抗原模拟多肽P1/Fas-Mip3β双表达重组质粒的构建及鉴定

Construction and identification of blood type B antigen mimetic polypeptide-Mip3β double expression recombinant plasmid
下载PDF
导出
摘要 目的构建并鉴定人血型B抗原模拟多肽、巨噬细胞炎症蛋白3β(Mip3β)双表达重组质粒。方法抗血型B抗体筛选噬菌体随机12肽库,筛选阳性噬菌体克隆P1,设计特异性引物扩增P1噬菌体DNA,同样设计特异性引物扩增PBluscript-Fas基因的跨膜区及胞内段,与P1酶切连接,最后与质粒PORF5-mMip3βv21扩增巨噬细胞炎症蛋白3β基因酶切连接,获得血型B抗原模拟多肽、Mip3β双表达重组质粒并进行鉴定,并在人黑色素瘤细胞株B16中转染与表达。结果和结论成功制备了血型B抗原模拟多肽、Mip3β双表达重组质粒,并在黑色素瘤细胞株B16中成功表达。 Objective To construct and identify blood type B antigen mimetic polypeptide-macrophage infliammatory protein 3β (Mip3β) double expression recombinant plasmid. Methods The positive phage clone P1 was obtained using phage random 12-mer peptide library. Specific primers were designed to amplify the phage DNA of P1 and transmembrane domain and inner segment of PBluscript-Fas gene. The products of the amplification were linked into Mip3βv21 to construct blood type B antigen mimetic polypeptide-Mip3β double expression recombinant plasmid. The recombinant plasmid was transfected into human melanoma cell line B16 to identify its expression. Results and conclusion Blood type B antigen mimetic polypeptide-Mip3β double expression recombinant plasmid is successfully obtained and expressed in human melanoma cell line B16.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2010年第8期1939-1942,共4页 Journal of Southern Medical University
关键词 人血型B抗原 摸拟多肽 巨噬细胞炎症蛋白3β 重组质粒 黑色素瘤细胞株B16 FAS基因 human blood type B antigen mimetic polypeptides Mip3[3 recombinant plasmid human melanoma cell lineB16 Fas
  • 相关文献

参考文献14

  • 1Gajewski TF. Failure at the effector phase: immue barriers at the level of the melanoma tumor microenvironment [J]. Clin Cancer Res, 2007, 13: 5256-61.
  • 2Turk M J, Guevara-Patino JA, Rizzuto GA, et al. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells[J]. J Exp Med, 2004, 200: 771-82.
  • 3Blank C, Brown I, Kacha AK, et al. ICAM-lcontribute to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivo[J]. J Immtmol, 2005, 174(6): 3416-20.
  • 4Gajewski TF, Meng Y, Harlin H, et al. Immune suppression in the tumor microenvironment [ J ]. J Immunother, 2006, 29(3): 233-40.
  • 5Ujjani C, Cheson BD. Monoclonal antibodies in advanced B-cell lymphomas[J]. Oncology, 2010, 24(2): 156-66.
  • 6Yakes FM, Chinratanalab W, Ritter CA, et al. Herceptin-induced inhibition of Phosphatidytinositol-3 Kinase and Akt is required for antibody-mediated effects on p27, Cyclin Dl and antitumor action [J]. Cancer Res, 2002, 62(14): 4132-41.
  • 7Ning YM, Gulley JL, Arlen PM, et al. Phase II trial ofbevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer[J]. J Clin Oncol, 2010, 20, 28 (12): 2070-6.
  • 8Croce M, Meazza R, Orego AM, et al, Sequential immunogene therapy with IL-12 and IL-15 enginecned neuroblastma cells curesmetastatie diease in syngereic mice [ J ]. Clin Cancer Res, 2005, 11(2): 735-42.
  • 9Yang SC, Hillinger S, Riedl K, et al. Intratumoral administration of dendritic cells overexpressing CCL-1 generates systemic antitumor responses and confers tumor immunity[J]. Clin Cancer Res, 2004, 10: 2891-901.
  • 10Shibaguchi H, Kuroki M, Kuroki M, et al. Cloning and sequencing of variable region cDNAs of a novel human monoclonal antibody to carcinoembryonic antigen, and generation of a single chain variable fragmented antibody[J]. Anticancer Res, 2004, 24(5): 3355-60.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部